These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 33492488)
21. Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-kit ligand. Li L; Meng XW; Krilis SA J Immunol; 1996 Jun; 156(12):4839-44. PubMed ID: 8648132 [TBL] [Abstract][Full Text] [Related]
22. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Akin C; Valent P; Escribano L Curr Allergy Asthma Rep; 2006 Jul; 6(4):282-8. PubMed ID: 16822380 [TBL] [Abstract][Full Text] [Related]
23. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Pardanani A Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340 [TBL] [Abstract][Full Text] [Related]
24. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Sánchez-Muñoz L; Teodósio C; Morgado JM; Escribano L Methods Cell Biol; 2011; 103():333-59. PubMed ID: 21722810 [TBL] [Abstract][Full Text] [Related]
25. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Johnson MR; Verstovsek S; Jorgensen JL; Manshouri T; Luthra R; Jones DM; Bueso-Ramos CE; Medeiros LJ; Huh YO Mod Pathol; 2009 Jan; 22(1):50-7. PubMed ID: 19116630 [TBL] [Abstract][Full Text] [Related]
26. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Pardanani A Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753 [TBL] [Abstract][Full Text] [Related]
28. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Chisholm KM; Merker JD; Gotlib JR; Gitana G; Lefterova M; Zehnder JL; George TI; Arber DA; Ohgami RS Am J Clin Pathol; 2015 Apr; 143(4):527-34. PubMed ID: 25780004 [TBL] [Abstract][Full Text] [Related]
29. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis. Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500 [TBL] [Abstract][Full Text] [Related]
30. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351 [TBL] [Abstract][Full Text] [Related]
31. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815 [TBL] [Abstract][Full Text] [Related]
33. Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients. Carosi G; Guabello G; Longhi M; Grifoni F; Passeri E; Corbetta S Mediators Inflamm; 2020; 2020():5785378. PubMed ID: 33144848 [TBL] [Abstract][Full Text] [Related]
34. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Pardanani A Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695 [TBL] [Abstract][Full Text] [Related]
35. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ; J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094 [TBL] [Abstract][Full Text] [Related]
36. The faces of mast cell disease: bone marrow infiltrates in 3 patients with systemic mastocytosis. Martinez AE; Medina AM; Hyde JA; Krill-Jackson E; Blaustein A; Schwartz M; Cabello-Inchausti B Ann Diagn Pathol; 2005 Apr; 9(2):81-5. PubMed ID: 15806514 [TBL] [Abstract][Full Text] [Related]
37. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780 [TBL] [Abstract][Full Text] [Related]
38. GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. Agopian J; Da Costa Q; Nguyen QV; Scorrano G; Kousteridou P; Yuan M; Chelbi R; Goubard A; Castellano R; Maurizio J; Teodosio C; De Sepulveda P; Asara JM; Orfao A; Hermine O; Dubreuil P; Brenet F Blood; 2021 Oct; 138(17):1590-1602. PubMed ID: 33974006 [TBL] [Abstract][Full Text] [Related]
39. Bone lesions in systemic mastocytosis: Bone histomorphometry and histopathological mechanisms. Bouvard B; Pascaretti-Grizon F; Legrand E; Lavigne C; Audran M; Chappard D Morphologie; 2020 May; 104(345):97-108. PubMed ID: 32127247 [TBL] [Abstract][Full Text] [Related]